Home Backup

Protecting Health, Promoting Life

The Kenya BioVax Institute was established in 2021 to manufacture and commercialize human vaccines and other health products and technologies.

Here is our Overview

Our Trending Story

Accelerating Vaccine and Therapeutic Production for Health Security in Africa

Featured Articles

Speech

Speech by The CEO/Director General, Dr Michael Lusiola, During The Visit by The World Bank Vice President for Human Development, Ms Mamta Murthi, At KBI HQ, on Wednesday 7th February 2024, At 2.30 Pm

June 14, 2024

Speech

Speech by The CEO/Director General, Dr Michael Lusiola, During The Field Visit by Regional Advisory Committee, at KBI HQ, On Friday 17th May 2024, At 9.00 Am

June 14, 2024

KBI through its research and development (R&D), partnerships and collaborations would contribute to the eradication of communicable and non-communicable diseases through novel vaccines and other biotherapeutics. Local vaccine manufacturing would assure access of vaccines to all in the country’s universal health coverage (UHC) agenda